Pestalozzi advises Johnson & Johnson Development Corporation (JJDC) in connection with Biocartis' series E fundraising
Biocartis SA, a molecular diagnostics company, completed a EUR 30 million Series E equity fundraising. This Series E round was entirely subscribed by existing shareholders such as RMM (Rudi Mariën), Debiopharm Diagnostics SA, PMV Tina Fund, Valiance, JJDC, Philips, the Wellcome Trust, Petercam, the family offices of Dr. Paul Janssen, Luc Verelst, Rudi Pauwels (founder of Biocartis) and some smaller shareholders, including some employees. Pestalozzi advised JJDC, the venture capital subsidiary of Johnson & Johnson, in this transaction on matters of Swiss law, like as in previous equity financings relating to Biocartis in 2010 (Series B), 2011 (Series C) and 2012 (Series D).